RSS   Newsletter   Contact   Advertise with us

Thermo Fisher Scientific to acquire Brammer Bio in $1.7 billion deal

Christian Fernsby ▼ | March 25, 2019
Thermo Fisher Scientific and Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, announced they have entered into a definitive agreement under which Thermo Fisher will acquire Brammer Bio for approximately $1.7 billion in cash.
Thermo Fisher Scientific
Acquisition   Brammer Bio is on track to deliver $250 million of revenue
Brammer Bio is a leading viral vector contract development and manufacturing organization (CDMO), enabling biopharma customers to deliver breakthrough medicines to patients by unleashing the potential of gene therapies and gene-modified cell therapies.

The business has nearly 600 employees at primary locations in Massachusetts and Florida.

Brammer Bio is on track to deliver $250 million of revenue in 2019 and expects to continue to exceed the projected market growth rate of 25 percent over the mid-term. Thermo Fisher expects the business to be accretive to adjusted earnings per share by $0.10 in the first full year of ownership.